The Next Lung Cancer A.C.T. program profiles
patients living with lung cancer and encourages the public to take
ACTion against lung cancer by being Aware, getting Checked and
Talking to their doctor
New survey shows 57 percent of Europeans
across nine countries lack knowledge of lung cancer; many lack an
understanding of the impact or severity of the disease
Today, actor Jack Huston, a star of the hit television show
Boardwalk Empire and the upcoming remake of Ben Hur, took on an
important new role as lung cancer advocate as he challenged
Europeans to A.C.T. – be Aware, get Checked, and Talk with their
doctor about lung cancer. After losing his grandfather to lung
disease and his best friend and mentor, Peter Blythe, to lung
cancer, Huston was motivated to take action by partnering with
Bristol-Myers Squibb Company (NYSE:BMY) and leading advocacy group
Lung Cancer Europe (LuCE) to ask the public, particularly those at
high risk, what’s their Next Lung Cancer A.C.T.?
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150928005331/en/
Lung cancer is the number one cancer killer in Europe with an
estimated 353,000 deaths each year – more than breast cancer,
colorectal and prostate cancers combined. In Europe, lung cancer is
the third most common cancer among women. Despite the growing
prevalence, a new survey conducted among more than 8,200
participants in nine European countries showed that lung cancer
knowledge is very low, with nearly six in 10 people (57%) surveyed
saying that they are not knowledgeable about the disease. Further,
one in five people (20%) could not identify the symptoms of lung
cancer, including persistent cough, and one in 10 people (10%) do
not know the risk factors, such as exposure to cigarette
smoking.
Huston, along with lung cancer advocates and oncologists,
unveiled the survey results at the European Cancer Congress (ECC)
2015 in Vienna, as well as a short film highlighting the personal
stories of lung cancer patients.
“Like many Europeans, I know firsthand the devastating impact
cancer can have on a family,” said Huston. “I’ve joined The Next
Lung Cancer A.C.T. in hopes of encouraging others to be mindful of
the risk factors and symptoms of lung cancer and the importance of
taking action now.”
Key findings of the survey showed:
- Six in 10 respondents (62%) believe
lung cancer is a smoker’s disease, although smoking is only one
risk factor for lung cancer
- 45 percent believe that breast cancer
is the leading cause of death among women as compared to 8 percent
who responded lung cancer
- Nearly half of all respondents (46%)
said they are not concerned about getting lung cancer, including 43
percent who have experience with lung cancer and 36 percent who are
daily smokers
- Eight in 10 people (83%) have never
spoken to their doctor about lung cancer; an equal number of
smokers (77%) also report this behavior
- Following the survey, the majority of
respondents (90%) expressed a willingness to take action to reduce
their risk of lung cancer, including reducing their exposure to
carcinogen (cancer-causing substances or agents) (50%), limit
exposure to secondhand smoke (48%), and talking to their doctor
(43%)
“It’s a pivotal time for lung cancer – the disease remains an
enormous public threat in Europe but we are seeing promising
research in the lung cancer space,” said LuCE board member and lung
cancer survivor, Regine Deniel Ihlen. “That is why now is the time
for people to act by being aware, taking steps to get checked and
having an ongoing dialogue with their physicians.”
“At ECCO we are committed to helping people understand the signs
that indicate that they may have cancer, as well as recognizing
ways in which the disease may be prevented,” said Professor Martine
Piccart, President of the European CanCer Organization (ECCO).
“That is why we are happy to be hosting the launch of this
campaign, and we wish it every success.”
“At Bristol-Myers Squibb, we are committed to fighting lung
cancer through our research in oncology and by supporting the
global lung cancer community,” said Emmanuel Blin, senior vice
president, Head of Commercialization, Policy and Operations,
Bristol-Myers Squibb. “The Next Lung Cancer A.C.T. represents our
ongoing dedication to helping to empower those with cancer by
providing them with knowledge to better understand the risks of
lung cancer and how to take action.”
About The Next Lung Cancer A.C.T.
The Next Lung Cancer A.C.T. is a public awareness campaign
designed to encourage the public, particularly those at high risk
of lung cancer, to take ACTion against the disease by being
Aware, getting Checked and Talking to their
doctor. The Next Lung Cancer A.C.T. is sponsored by Bristol-Myers
Squibb, in collaboration with Lung Cancer Europe (LuCE). For more
information on the campaign please visit
www.TheNextLungCancerACT.eu.
About the Survey and TNS
TNS conducted the survey. TNS, the world’s largest custom
research agency, is a well-recognized research group for their
quality and authoritative research.
Participants in the 12-question, self-administered online
omnibus survey were 8,263 Europeans, ages 16-54 across nine
different countries in Europe: Austria, Denmark, Germany, Great
Britain, Italy, Netherlands, Spain, Switzerland and Turkey. The
survey was conducted between July 30, 2015 and August 7, 2015. The
results were tested at 95% significant. At 95% confidence level, if
the study were repeated, the results would not fluctuate more than
3.0-3.4 percentage points in either direction for the population
surveyed in each country.
About Lung Cancer
Lung cancer is the leading cause of cancer deaths globally,
resulting in more than 1.5 million deaths each year, according to
the World Health Organization (WHO). In Europe alone, lung cancer
is responsible for an estimated 353,000 deaths from the disease
every year – more than breast cancer, colorectal and prostate
cancers combined. It has the highest economic burden of all cancers
in the European Union, costing an estimated €18.8 billion or 15
percent of overall cancer costs.
About LuCE
Lung Cancer Europe (LuCE) is a voice of lung cancer patients,
their families and survivors at a European level. LuCE provides a
European platform for already existing lung cancer patient advocacy
groups and supports the establishment of national lung cancer
patient groups in different European countries where such groups do
not yet exist.
LuCE aims to raise awareness about inequities regarding the
access to lung cancer treatment and care in Europe. Moreover, it
advocates European policies that will lead to improvements in lung
cancer prevention, early detection, treatment and care. LuCE also
supports national lung cancer patient groups in helping raise
awareness for lung cancer among the European public.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company
committed to discovering, developing and delivering innovative
medicines that help patients prevail over serious diseases. For
more information about Bristol-Myers Squibb, visit www.bms.com, or
follow us on Twitter at http://twitter.com/bmsnews.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150928005331/en/
Media:Bristol-Myers SquibbChristina Trank,
732-551-5343christina.trank@bms.comorOgilvy Public
RelationsMelissa Luke,
518-466-6619melissa.luke@ogilvy.comorChris Caudle,
00447958585406chris.caudle@ogilvy.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024